Table 1.
Fc-glycopeptides analysis of mAbs with homogenous glycan.
| Deduced glycan | Relative peak area (%) of each glycopeptide against total peak area of EEQYNSTYR peptides |
|||
|---|---|---|---|---|
| G0F-mAb | G1aF-mAb | G1bF-mAb | G2F-mAb | |
| G0F lacking a GlcNAc | –a | 0.7 | 0.6 | – |
| G0F | 98.4 | 1.1 | 0.2 | – |
| G1F (G1aF + G1bF) | 0.8 | 97.9 | 98.4 | 0.9 |
| G2F | 0.3 | 0.3 | 0.9 | 97.9 |
| (Fucα1-6)GlcNAcb | 0.5 | – | – | 1.2 |
| GlcNAcb | – | – | – | – |
| non-glycosylated peptide | – | – | – | – |
EEQYNSTYR peptide was obtained by tryptic digestion of mAbs. a, not detected; b, reducing terminal N-acetylglucosamine from Fc-glycan; underline, N-glycosylation site at Asn 297(EU numbering). Structures of G0F, G1aF, G1bF, and G2F: see Figure 1. GlcNAc, N-acetylglucosamine; Fuc, fucose.